Eosinophils are major effector cells for the development of transplant arteriosclerosis and depend on the presence of IL-4. by Ensminger, S, Witzke, O, Spriewald, B, Sorensen, H, Morris, P, Rahemtulla, A, Rose, M, Wood, K

Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. by Rahemtulla, A, Kündig, T, Narendran, A, Bachmann, M, Julius, M, Paige, C, Ohashi, P, Zinkernagel, R, Mak, T

An in vivo model of reverse signalling through CD40L. by Thomson, K, Manis, J, Jones, M, Alsheikhly, R, Leung, R, Davidson, L, Mcmichael, A, Alt, F, Rahemtulla, A

Human invariant NKT cells are required for effective in vitro alloresponses. by Patterson, S, Kotsianidis, I, Almeida, A, Politou, M, Rahemtulla, A, Matthew, B, Schmidt, R, Cerundolo, V, Roberts, I, Karadimitris, A

Critical role for IL-4 in the development of transplant arteriosclerosis in the absence of CD40-CD154 costimulation. by Ensminger, S, Spriewald, B, Sorensen, H, Witzke, O, Flashman, E, Bushell, A, Morris, P, Rose, M, Rahemtulla, A, Wood, K

Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids by Xu, K, Antonopoulos, A, Spanoudakis, E, Parry, S, Chaidos, A, Hu, M, Butters, T, Dell, A, Rahemtulla, A, Horwood, N, Karadimitris, A

Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification by Anand P, Elsafa E, Privitera R, Naidoo K, Yiangou Y, Donatien P, Gabra H, Wasan H, Kenny L, Rahemtulla A, Misra P

Get full text

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. by Chaidos, A, Patterson, S, Szydlo, R, Chaudhry, M, Dazzi, F, Kanfer, E, McDonald, D, Marin, D, Milojkovic, D, Pavlu, J, Davis, J, Rahemtulla, A, Rezvani, K, Goldman, J, Roberts, I, Apperley, J, Karadimitris, A

The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Soci... by Bird, J, Fuge, R, Sirohi, B, Apperley, J, Hunter, A, Snowden, J, Mahendra, P, Milligan, D, Byrne, J, Littlewood, T, Fegan, C, McQuaker, G, Pagliuca, A, Johnson, P, Rahemtulla, A, Morris, C, Marks, D

Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. by Chaidos, A, Barnes, C, Cowan, G, May, P, Melo, V, Hatjiharissi, E, Papaioannou, M, Harrington, H, Doolittle, H, Terpos, E, Dimopoulos, M, Abdalla, S, Yarranton, H, Naresh, K, Foroni, L, Reid, A, Rahemtulla, A, Stumpf, M, Roberts, I, Karadimitris, A

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT. by Innes, A, Beattie, R, Sergeant, R, Damaj, D, Foroni, L, Marin, D, Kanfer, E, Mielke, S, Milojkovic, D, MacDonald, D, Pavlu, J, Rahemtulla, A, Roberts, I, Slade, D, Bray, E, Goldman, J, Apperley, J, Szydlo, R, Dazzi, F, Rezvani, K

Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease by Ersek, A, Xu, K, Antonopoulos, A, Butters, TD, Santo, AE, Vattakuzhi, Y, Williams, LM, Goudevenou, K, Danks, L, Freidin, A, Spanoudakis, E, Parry, S, Papaioannou, M, Hatjiharissi, E, Chaidos, A, Alonzi, DS, Twigg, G, Hu, M, Dwek, RA, Haslam, S, Roberts, I, Dell, A, Rahemtulla, A, Horwood, NJ, Karadimitris, A

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. by Chaidos, A, Caputo, V, Gouvedenou, K, Liu, B, Marigo, I, Chaudhry, M, Rotolo, A, Tough, D, Smithers, N, Bassil, A, Chapman, t, Harker, N, Barbash, O, Tummino, P, Al-Mahdi, N, Haynes, A, Cutler, L, Le, B, Rahemtulla, A, Roberts, I, Kleijnen, M, Witherington, J, Parr, N, Prinjha, R, Karadimitris, A